Post-earnings recap
Reported
Thu, Nov 8, 2012
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Biocryst Pharmaceuticals is still facing challenges, particularly in generating revenue. The stock's significant drop of 40.35% reflects investor concerns about the company's future performance and lack of guidance. The positive surprise in EPS may not have been enough to offset worries about revenue and overall strategy.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.19 | N/A | +17.39% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced in the quarter. They emphasized a commitment to improving operational performance.
Management did not provide specific guidance for future quarters.
The company is focusing on its pipeline and operational efficiencies.